-
2024-510620-39-00
5
2021-04-19
Advanced RCC with clear cell component
-
2022-502705-15-00
5
2021-03-08
High-risk muscle-invasive bladder cancer
-
2023-507338-26-00
5
2021-02-01
Histologically documented gastric or gastroesophageal junction adenoca
-
2024-515944-22-00
4
2021-01-19
BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
-
2023-507475-21-00
10
2021-01-18
Lung Cancer, Non-Small Cell
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2023-503384-41-00
5
2020-12-22
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
-
2023-504830-23-00
5
2020-12-16
B-cell Lymphoma
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2024-515331-30-00
7
2020-10-30
Primary Central Nervous System Lymphoma (PCNSL)
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2024-516673-68-00
5
2020-10-27
Human papillomavirus (HPV)-positive oropharyngeal cancer
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2024-518506-41-00
9
2020-10-05
metastatic castrate resistant prostate cancer
-
2023-504998-20-00
5
2020-09-18
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2024-515560-30-00
7
2020-03-05
Advanced-stage, relapsed/refractory cancer
-
2024-515434-32-00
9
2020-02-12
Low-risk gestational trophoblastic neoplasia
-
2022-501973-37-00
5
2020-01-30
Endometrial cancer
-
2022-502478-18-00
4
2019-12-20
Acute Myeloid Leukemia (AML)
-
2024-514829-36-00
5
2019-12-02
High-risk biochemically-relapsed prostate adenocarcinoma following rad
-
2024-510776-20-00
5
2019-10-25
Female or male patients with histologically confirmed HR-positive, HER
-
2024-515616-47-00
5
2019-10-03
Metastatic Renal Cell Carcinoma
-
2024-512555-21-00
5
2019-09-18
Metastatic colorectal cancer